Verily collaborates with Janssen to launch COVID-19 immune response study
Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes.
The study will be launched by Verily’s Project Baseline testing program and intends to collect biological information and real-world data in the weeks soon after a person tests positive for COVID-19.
The aim is to recognize early warning biomarkers, which could help guide healthcare providers through future treatments and potentially predict whether an individual’s case may turn ...
